Loading...
Loading...
Watson Pharmaceuticals, Inc.
WPI today confirmed that Actavis, Inc., which was acquired by Watson
in October, has filed an Abbreviated New Drug Application (ANDA) with the U.S.
Food and Drug Administration (FDA) seeking approval to market bortezomib.
Actavis' ANDA product is a generic version of Millennium Pharmaceuticals'
Velcade ^ ® (bortezomib), which is a proteasome inhibitor, for intravenous or
subcutaneous administration, approved for the treatment of patients with
multiple myeloma and patients with mantle cell lymphoma who have received at
least one prior therapy.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in